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Accepted 3 September 2014; Published online 7 October 2014AbstractObjectives: In randomized trials, the primary analysis should be consistent with the intention-to-treat (ITT) principle and should
address missing data appropriately to draw valid inferences. This review focuses on current practices relating to the ITT principle and
methods to handle missing data in the major musculoskeletal journals.
Study Design and Setting: A systematic review of randomized trials published in 2010 and 2011 in five musculoskeletal journals was
performed.
Results: We reviewed 91 trials: 38% performed a full ITT analysis (analyzing outcome data for all randomized participants) and 31%
performed a partial ITT analysis (excluding participants with no follow-up data). The overall median dropout was 12%; 60% of trials had
more than 10% dropouts, and 32% of trials had more than 20% dropouts. Among those that performed an ITT analysis, the majority adopted
a form of single imputation; last observation carried forward was the designated approach in most cases. Mixed models for repeated mea-
sures and/or multiple imputations were limited to eight trials.
Conclusion: It appears that many trials reporting missing data are inappropriately analyzed and may therefore be prone to biased es-
timates and invalid inferences.  2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Intention-to-treat (ITT) analysis is the preferred method
for randomized controlled trials (RCTs) with a superiority
design. The ITT principle states that an analysis should
include all study participants in the groups to which they
were randomized, regardless of any departures from the
original assigned group [1]. This principle helps to preserve
the benefits of randomization, which is intended to ensure
that differences in outcome observed between groups are
solely the result of the treatment [2,3], and to reduce the
risk of selection bias [4,5]. In an ideal setting, all subjects
enrolled in an RCT would follow the study protocol and
complete their allocated treatment as detailed therein, thus
contributing data that are complete in all respects [6]. How-
ever, this is rarely achieved in practicedparticularly under
pragmatic trial conditions [7]. Moreover, to provide an un-
biased estimate of treatment effect, randomization alone isFunding: None.
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licenses/by-nc-nd/3.0/).insufficientdit is also important to obtain complete data on
all randomized subjects and include these in the analysis
[8]. Some authors, however, describe an analysis as ITT
without regard to this requirement to include data for all
randomized participants in the analysis [9]. We refer to
an approach that deviates from a full ITT (FITT) analysis
in this waydby retaining treatment group membership as
per random allocation but excluding participants with no
follow-up datadas a partial ITT (PITT) analysis. (The term
‘‘modified intention-to-treat’’ has frequently been used to
describe this approach [9], but this term has been criticized
for being ambiguous and lacking clarity regarding the
exclusion of data [10,11].)
Because of a perceived misuse of the term ‘‘intention-to-
treat’’ [10e12], item 16 in the 2010 CONSORT statement
was updated to include a more explicit request for group-
wise details on the number of participants included in each
analysis and whether the analysis was randomized by
groups [12]. Non-ITT analyses such as an ‘‘as-treated’’
(AT) analysis, which groups participants according to treat-
ment received rather than according to randomization, and
a ‘‘per-protocol’’ (PP) analysis, which omits participants
who do not follow the study protocol, are not protectedess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 In accordance with the intention-to-treat (ITT)
principle, most trials analyzed data by the groups
to which subjects were randomized regardless of
the intervention received. However, many failed
to obtain outcome data for all randomized subjects
and/or include all subjects in the primary analysis.
 On average, the dropout rate was a little over 10%,
and because most trials failed to use appropriate
statistical methods to account for missing data, it
is likely that descriptive data and inferential esti-
mates of treatment effect were biased, given that
missing data probably differ from reported data.
What this adds to what was known?
 Many trials are not carrying out an ITT analysis as
recommended by guidelines. The violation of the
ITT approach largely concerns inappropriate
handling of missing data.
 The present study found sensitivity analyses to be
infrequently and inappropriately used and insuffi-
ciently reported.
 It appears that only modest progress has been
made, subsequent to previous reviews, in reducing
the large proportion of trials that are inappropri-
ately analyzed.
What is the implication and what should change
now?
 ITT is the gold standard approach to the analysis of
randomized clinical trials with hypothesis testing
in respect of superiority of treatment. However, de-
viation from the ITT approach is common, partic-
ularly in respect of analysis of incomplete data,
which may result in biased estimates and give rise
to invalid inferences. Trialists should ensure that
missing values are handled judiciously and apply
methods of analysis that make appropriate assump-
tions about the missing data.
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baseline variables [13].
The basic issue in an analysis of trial data with missing
values is the selection of an ITT analysis data set. White
et al. [14] stated that a true ITT analysis is possible only
when there is no missing outcome data. However, in prac-
tice, no matter how well designed and implemented a study,
missing data are almost inevitable [15]. Hence, the benefits
of randomization may be compromised; any statisticalinferences, therefore, rely on additional assumptions. Incom-
plete outcome data can lead to problems such as loss of ef-
ficiency due to reduced sample size anddif data are missing
disproportionally in each arm and/or for different reasonsd
bias in the estimate of treatment effect due to differences be-
tween the observed and unobserved data [16]. Therefore, a
full data set requires either imputation of missing values
or modeling of unobserved data [17]. Any analysis of RCTs
with incomplete data is based on specific assumptions on the
missing data mechanism, such as missing completely at
random (MCAR), missing at random (MAR), or missing
not at random (MNAR) [18,19]. Under the MCAR mecha-
nism, missingness is independent of both observed data
(eg, baseline covariates and observed responses) and unob-
served data (those observations that would have been re-
corded if the patients had stayed in the study). Under the
MAR mechanism, missingness depends on observed data
but not on unobserved data. Under the MNAR mechanism,
missingness depends on unobserved data.
As trials with missing data may not retain the balance of
randomization, the basis for statistical inference is lost
[6,20], and there is no longer a statistical rationale to guar-
antee lack of bias for the estimation of the parameter and its
associated confidence intervaldeven if the study is
assumed to be free of other risks of bias, such as non-
masked evaluation. Identification of the underlying missing
data mechanism is important to carry out appropriate
formal analyses of data with missing values; however, it
is impossible to identify this mechanism with certainty
based on the observed data alone [21]. Missing data should
therefore be considered at the design, conduct, and analysis
stages of a trial [14,22,23]. First, trialists should attempt to
minimize missing data in the first instance by following up
all randomized subjects, even if they withdraw from an
allocated intervention. Second, analysts should perform a
primary analysis with a plausible assumption on the mech-
anism of missing data. Third, sensitivity analyses should
explore the robustness of the results to a range of alterna-
tive plausible assumptions regarding missingness.
A few studies [24e28] have examined practices
regarding the use of the ITT principle and/or the reporting
and handling of missing data in RCTs published in general
medical journals. Additionally, two studies have assessed
these issues in RCTs in musculoskeletal conditions [29,30].
These studies found many instances in which analyses
were poorly defined and described and noted variation in
practice regarding the ITT principle and the handling of
missing data. For example, Gravel et al. [27] evaluated
403 reports of RCTs published in 2002 in 10 medical jour-
nals and reported that 62% of the trials analyzed their pri-
mary outcome on an ITT basis. However, only 39% of trials
analyzed all subjects as randomized. The study also re-
ported that 60% of trials had at least some missing data
and most of these trials (59%) excluded subjects with
missing data from the primary analysis. In the musculoskel-
etal field, Baron et al. [29] examined the use of the ITT
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riority RCTs assessing structural outcomes in rheumatic
diseases published between 1994 and 2003. These authors
reported that an FITT analysisdone that includes all sub-
jects as randomizeddwas only applied in 7% of these
RCTs. They also noted that almost 68% of 63 articles in
which missing data information had been reported had
more than 10% missing data and approximately one-third
had more than 20%. However, only a quarter of the articles
reported statistical methods for handling missing data.
Henschke et al. [30] reported the trend over time
(1980e2008) in the quality of 157 RCTs of interventions
for chronic low back pain. Their evaluation was based on
11 criteria described by Koes et al. [31], of which two
are closely linked to the ITT principle. Criterion 9 is ful-
filled if the percentage of withdrawals and dropouts does
not exceed 20% for short-term follow-up and 30% for
long-term follow-up and if such dropouts are described
with reasons; for most years of the study period, more than
one-third of the reviewed RCTs published in the year con-
cerned failed to fulfill the criterion. Criterion 11 is fulfilled
if all randomized patients are analyzed in the group to
which they were allocated by randomization for the pri-
mary effect measurement, minus missing values, irrespec-
tive of noncompliance, and cointerventions; fewer than
60% of the RCTs fulfilled this criterion.
Previous reviews [26,28,29] have reported that listwise
deletion of caseswith one ormoremissingvalueswas themost
common approach in the primary analysis. This approach is
likely to provide a biased result (unless the mechanism is
MCAR), inefficient estimates (ie, estimates that have wide
confidence intervals through lack of precision), and loss of sta-
tistical power [22]. These reviews also found that single impu-
tations were widely used to create a full data set. Carrying the
last observation forward was a frequently used approach
among the single imputations; however, the assumption of
zero change after dropout is not justifiable in most trials
[22]. Several guidelines and recommendations issued on
missing data in RCTs [17,23,32] have advocated, as a starting
point, methods of analysis that are valid underMARdsuch as
methods based on multiple imputations (MI), likelihood-
based methods (eg, mixed models for repeated measures
[MMRMs] [33]), or moment-basedmethods such asweighted
generalized estimating equations (weighted GEE) [34,35].
However, previous reviews [26,28,29,36] on methods of
handling missing data in RCTs have found that these recom-
mended approaches were limited to a small fraction of trials.
Pragmatic RCTs differ from the archetypal clinical trial
that uses placebo-controlled methods to ensure blinding,
rigid treatment procedures, and objective measurement of
outcome [37]. One clinical area where pragmatic trials
abound is in musculoskeletal conditions, where the aims
of treatment are mainly to reduce the burden of disease
and disability under everyday clinical conditions (ie, the
effectiveness rather than the efficacy of a treatment);
accordingly, the outcome measures are mostly subjectiveand relate to participants’ well-being, not the quantification
of laboratory data. Owing to their chronic nature, many
musculoskeletal conditions necessitate long-term trials,
which are prone to loss to follow-up. Each of these features
may predispose to missing values.
Against this background, our study sought to examine cur-
rent practice relating to ITT analysis and methods to handle
missing data in published trials inmusculoskeletal conditions.
Specifically, the study had the following objectives:
1. To describe the extent of adherence to random
allocation,
2. To describe the extent of reported dropout and the
appropriateness of the analytical methods used to
handle missing data,
3. To assess the use of sensitivity analyses.2. Methods
2.1. Selection of studies
Five journals (Annals of the Rheumatic Diseases,
Arthritis & Rheumatism, Journal of Rheumatology, Pain,
and Rheumatology) were selected as sources of RCTs in
the areas of arthritis and musculoskeletal conditions. Jour-
nals with high impact factors were targeted, as it was
considered important to evaluate ‘‘best’’ statistical practice
in this field, for which the impact factor was taken as a
proxy. The impact factors ranged from 3.6 (Journal of
Rheumatology) to 9.1 (Annals of the Rheumatic Diseases).
Only parallel-arm individual-level RCTs using a superi-
ority design and reporting on the primary outcome of the
study were included in this study. Additional exclusion
criteria were as follows:
1. Pilot/feasibility studies, as these mainly aim to
demonstrate the feasibility and/or affordability of
subsequently conducting a large similar study, rather
than to detect a true between-group difference with
sufficient power.
2. Trials with fewer than 50 randomized subjects, as the
small sample size could impose limitations on
possible methods of analysis.
3. Publications based on an interim analysis (ie, where
the primary analysis was centered on an outcome
measured at a time point earlier than the designated
primary end point).
4. Extended follow-up studies (those only reporting out-
comes beyond the primary end point)
5. Studies with survival outcomes, as standard survival
models take into account missingness through nonin-
formative censoring.2.2. Search strategy and data extraction
A search was performed for all reports of RCTs published
between January 1, 2010, and December 31, 2011, focusing
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tion’’, ‘‘randomized’’, ‘‘randomised’’, ‘‘randomly’’, or
‘‘random’’ in the titles or abstracts to identify relevant cita-
tions. Fig. 1 illustrates the selection procedure and indicates
the reasons for exclusions.
Using a proforma based on recent recommendations
[12,23,38], data were extracted from each of the 91 eligible
trial reports. Information was obtained on basic characteris-
tics of the trials, participant exclusions and withdrawals,
sample size calculation, measurement of outcomes, proto-
col deviations, methods used to handle missing data, statis-
tical analyses performed, and sensitivity analyses
conducted. To check consistency of data extraction, the
process was repeated after a period of several months,
and the data extraction was verified by a second investi-
gator in 20% of randomly selected reports.
Data extraction centered on the primary outcome at the
study primary end point. The primary outcome was identi-
fied from the definition given in the report (eg, in the study
objectives) or from the details on the sample size calcula-
tion. If more than one primary outcome was reported, the
first one listed was used. If, in the case of multiple
follow-ups, the primary end point was not explicitly identi-
fied, it was taken to be the final measurement.2.3. Dropout rate
Dropouts were subjects who did not complete the pri-
mary outcome assessment at the primary end point,120 Ann Rheum Dis
64 Arthritis Rheum 80 Reviews an
70 J Rheumatol 46 Non-random
86 Pain 20 Secondary
65 Rheumatology 20 Editorials/l
15 Phase I an
10 Studies wit
6 Cross-over
4 Pilot/feasib
3 Economic 
2 Non-human
67 Ann Rheum Dis
36 Arthritis Rheum 34 Secondary
30 J Rheumatol 18 Non-random
47 Pain 14 Studies wit
19 Rheumatology 11 Reviews an
9 Phase I an
8 Cross-over
6 Pilot/feasib
5 Studies wit
2 Non-human
1 Economic 
405 Citations:
206 Excluded 
199 Full articles reviewed:
91 Parallel-group 
randomized trials
Excluded:108
Fig. 1. Identification of randomized trials frwhereas completers were those who completed the assess-
ment. Dropouts include individuals lost to follow-up
(through nonresponse) and those not followed up because
of protocol violations such as ineligibility or treatment
crossover. The dropout rate was calculated as the difference
between the number randomized and the number remaining
in the trial (completers) at the primary end point, divided by
the number randomized. In trials with repeated follow-ups,
the dropouts were classified as either ‘‘early dropouts,’’
defined as subjects who did not complete any follow-up
assessment on the primary outcome, or ‘‘late dropouts,’’
defined as those who completed at least one follow-up
assessment before dropping out.2.4. Classification of analysis strategies
The analysis strategy used in the reviewed reports was
categorized as FITT, PITT, complete case (CC), PP, or
AT. The definition of each category is given in Table 1.
FITT is an analysis of data as randomized and includes data
on all randomized subjects through either imputation or
modeling of any missing data. PITT denotes an analysis
restricted to a subset of the FITT sample where the subsam-
ple excludes early dropouts (in trials with repeated follow-
ups). The purpose of this classification is to highlight the
exclusion of early dropouts from the primary analysis. In
trials with a single follow-up, the exclusions lead to a CC
analysis as there is no scope for further follow-up data.
Such exclusions of dropouts with no follow-up data mayd analysis of multiple trials
ized studies
 publications/reports of extended follow-up trials
etters
d II studies
h sample size less than 50
 trials
ility studies
evaluation studies
 studies
 publications/reports of extended follow-up trials
ized studies
h sample size less than 50
d analysis of multiple trials
d II studies
 trials
ility studies
h survival outcome
 studies
evaluation studies
based on review of title, abstract & keywords:
om January 2010 to December 2011.
Table 1. Classification of analysis strategy used in trial reports
Statistical analysis strategy Explanation
Full ITT (FITT) analysis All randomized subjects included in the analysis and analyzed as randomized.
Partial ITT (PITT) analysis Analysis excludes only those randomized subjects who did not provide any follow-up data from an
FITT sample in trials with repeated follow-ups.
Complete-case (CC) analysis Analysis includes only those randomized subjects who completed the primary outcome measurement
at the primary end point (ie, this analysis excludes subjects with missing data at the primary end
point), and analysis is performed on the basis of randomized group allocation.
As-treated (AT) analysis Subjects analyzed as treated, regardless of the treatment to which they were assigned.
Per-protocol (PP) analysis Analysis includes subjects who completed the trial in full accordance with the study protocol.
Abbreviation: ITT, intention to treat.
Table 2. Description of trials (n 5 91) included in the study
Description of the trials No. of trials (%)
Journal
Annals of the Rheumatic Diseases 31 (34.1)
Arthritis & Rheumatism 16 (17.6)
Journal of Rheumatology 11 (12.1)
Pain 27 (29.6)
Rheumatology 6 (6.6)
Year of publication
2010 38 (41.8)
2011 53 (58.2)
Multicenter trials 52 (57.1)
Number of subjects per triala
!100 36 (39.6)
100e499 41 (45.0)
500 and above 14 (15.4)
Number of arms per trial
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sion is protected against biased selection of an outcome
or a data-driven preference for a particular analysis. Such
protection is afforded when the criteria for exclusion of par-
ticipants from the analysis are prespecified in the protocol
and are not based on information related to either treatment
allocation or events or outcomes that occurred after
randomization [3]. However, such exclusions should be
limited to avoid selection bias [3]. Ideally, such decisions
should also be made by a blind or independent observer.
White et al. [39] argued that including all randomized sub-
jects in an analysis of an outcome with missing data is
insufficient; one should also consider an appropriate
method to handle the missing data.
2.5. Classification of methods to handle missing data
The method used, if any, to deal with missing data was
classified as
1. Listwise deletion
2. Single imputation, such as baseline observation car-
ried forward (BOCF), last observation carried for-
ward (LOCF), worst observation carried forward,
nonresponder (ie, treatment failure) imputation,
regression method, or linear extrapolation method
3. MI, whereby missing values are replaced by a set of
values generated from the posterior predictive distri-
bution of missing data
4. Statistical models that can include all randomized
subjects without imputation of missing values (eg,
MMRM)
The validity of the aforementioned methods is, as previ-
ously noted, dependent on the plausibility of the missing
data assumption.2 67 (73.6)
3 15 (16.5)
O3 9 (9.9)
Type of primary outcome measure
Categorical 19 (20.9)
Numericalb 72 (79.1)
Number of follow-up assessments
Single 11 (12.1)
Repeated 80 (87.9)
a Number of subjects randomized.
b Thirteen trials analyzed these outcomes as categorical.3. Results
3.1. Characteristics of included trials
A description of the 91 trials (list provided in Appendix
at www.jclinepi.com) included in the review is presented in
Table 2. The majority included a numerical primary
outcome measure. Among the 72 trials that detailed asample size calculation, only 28 (39%) made adjustment
for attrition. In 18 of 72 trials (25%), the number of subjects
randomized was less than the calculated sample size (the
shortfall ranged from 1% to 53%; median, 5%). Most of
the trials (79 of 91; 87%) in this review followed the CON-
SORT statement [40] in reporting armwise flow of partici-
pants through the trial.3.2. Analysis strategy
Table 3 indicates the analysis strategy followed in the
primary analysis of the trials. In all but one trial, subjects
were analyzed as randomized (though 10 trials reported
crossover of treatment after randomization). An FITT anal-
ysis was performed in 34 trials (37%); in four trials, there
were no missing data at the primary end point, and in the
remaining 30 trials, all randomized subjects were included
in the analysis through either imputation of missing values
Table 3. Analysis strategy followed in the primary analysis
Analysis strategy
Trials with
single
follow-up
(n [ 11)
Trials with
repeated
follow-ups
(n [ 80)
Total
(n [ 91)
Full ITT 2 (18.2) 32 (40.0) 34 (37.4)
Partial ITT N/A 28 (35.0) 28 (30.7)
Complete-case analysis 7 (63.6) 17 (21.3) 24 (26.4)
As-treated analysis 0 (0.0) 1 (1.2) 1 (1.1)
Per-protocol analysis 2 (18.2) 2 (2.5) 4 (4.4)
Abbreviations: ITT, intention to treat; N/A, not applicable.
Data are counts (%).
Table 4. Methods used to handle late dropouts who had completed
at least one follow-up assessment
Method used in
primary analysis
Percentage of late dropouts
O0e10% O10e20% O20% Total
No imputation
Excluded 10 (29.5) 6 (33.3) 2 (9.1) 18 (24.0)
MMRM 2 (5.9) 1 (5.6) 3 (13.6) 6 (8.0)
GEE 1 (2.9) 1 (4.6) 2 (2.7)
Single imputation
LOCFa 7 (20.6) 7 (38.8) 8 (36.3) 23 (30.7)
NRI 7 (20.6) 2 (11.1) 3 (13.6) 12 (16.0)
BOCF 1 (2.9) 3 (13.6) 4 (5.3)
Regression
imputation
1 (2.9) 1 (5.6) 2 (2.7)
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of trials (17 of 80) with repeated follow-ups and 64% of tri-
als (7 of 11) with a single follow-up excluded all dropouts
from the primary analysis. Other protocol violations were
reported in 22 trials, and four of them followed a PP strat-
egy as the primary analysis. A PITT analysis (excluding
early dropouts) was performed in 28 of 80 trials (35%) with
repeated follow-ups.
3.3. Dropouts
Fig. 2 displays the percentage of trials with various
levels of dropout. Eighty-six trials (95%) had some subjects
with missing outcome data at the primary end point. The
median dropout rate was 12% [interquartile range (IQR),
7e24%; range, 0e51%]. The median (IQR) dropout rate
was 11% (5e21%) for trials using FITT and CC analysis
methods and 20% (11e31%) for trials using PITT.
Among 11 trials with single follow-up, 10 (91%) reported
dropouts [median (IQR) dropout rate of 9% (6e12%)].
Among 80 trials with repeated follow-ups, 39 (49%) reported
early dropouts [median (IQR) dropout rate of 3% (1e9%)],
and 75 trials (94%) reported the presence of late dropouts [me-
dian (IQR) dropout rate of 10% (6e21%)].
3.4. Dealing with dropouts
Among the 10 trials with single follow-up reporting
dropouts, nine excluded these dropouts from analysis,Fig. 2. The distribution of the trials (n 5 90) based on the percentage
of dropouts. The number above each bar indicates the number of tri-
als. One trial did not report the dropout rate.whereas the remaining trial used BOCF. Among the 39 tri-
als with repeated follow-ups reporting early dropouts, 36
(92%) excluded these dropouts from the analysis (28 fol-
lowed PITT, 7 followed CC, and 1 followed AT analysis)
and the remaining three used BOCF, MI, or MMRM to
handle the missing data.
Among the 75 trials with late dropouts, 46 (61%) per-
formed some sort of imputation (Table 4). Among the 26
trials (35%) that did not use any imputation, eight used
analysis methods that make full use of all available data
through modeling of incomplete repeated measures data
(MMRM in six and GEE in two) and the remaining 18
excluded the dropouts from the primary analysis. LOCF
was the most frequent imputation approach, used in 23 tri-
als (31%).
3.5. Sensitivity analyses
Eighteen (21%) of 86 trials with missing outcome values
at the primary end point reported a sensitivity analysis to
assess the robustness of inferences from the primary anal-
ysis to a range of alternative plausible assumptions
regarding missingness. The sensitivity analyses were per-
formed in trials with relatively high proportions of missing
data (median, 24%; IQR, 17e33%). Either exclusion of
subjects with missing data (ie, listwise deletion) or a singleLOCF þ NRIb 1 (5.6) 1 (1.3)
LOCF þ WOCFc 1 (4.6) 1 (1.3)
Linear
extrapolation
1 (2.9) 1 (1.3)
Multiple imputation 2 (5.9) 2 (2.7)
No details 2 (5.9) 1 (4.6) 3 (4.0)
Total 34 (100) 18 (100) 22 (100) 75 (100)
Abbreviations: MMRM, mixed model for repeated measures; GEE,
generalized estimating equations; LOCF, last observation carried for-
ward; NRI, nonresponder imputation; BOCF, baseline observation car-
ried forward; WOCF, worst observation carried forward.
Data are counts (%).
a Dropout rate not reported in one trial.
b Trials in which subjects dropping out were treated as nonre-
sponders when dropout is due to adverse events or lack of effective-
ness, otherwise imputed with LOCF.
c Trials imputed with WOCF when dropout is due to adverse events
or inefficacy, otherwise imputed with LOCF.
21R. Joseph et al. / Journal of Clinical Epidemiology 68 (2015) 15e24imputation method was the designated sensitivity analysis.
Very few trials (6 of 18; 33%) presented the results of their
sensitivity analysis, whereas the others just reported that a
sensitivity analysis had been performed and indicated that
the findings from the primary analysis were supported by
those of the sensitivity analysis.
3.6. Cautionary notes on missing data
We further reviewed all 55 trial reports with 10% or
more missing data to determine how the authors addressed
the uncertainty due to missing data in their interpretation of
results. Among those trials that did not report a sensitivity
analysis, none attempted to highlight the uncertainty
around their findings due to the missing data, apart from
a few instances in which dropout was briefly identified as
a limitation of the study.4. Discussion
In accordance with the ITT principle, most trials in the
review analyzed data by the groups to which subjects were
randomized, regardless of the intervention received. How-
ever, many of these trials failed to obtain outcome data
on all randomized subjects and/or include all subjects in
the primary analysis. The average dropout rate was a little
over 10%, and because most trials failed to use appropriate
statistical methods to account for missingness, it is likely
that descriptive data and inferential estimates of treatment
effect were biased, given that missing data likely differ
from reported data. In total, only one-third of trials used
an FITT approach for the primary analysis. This proportion
is comparable with those reported by Kruse et al. [25] and
Gravel et al. [27], but higher than that reported by Baron
et al. [29]. The lower proportion noted by Baron et al.
[29] may reflect changing practice since 2003 or may be
due to their specific focus on structural outcomes in trials
of rheumatic diseases without regard to whether these were
a primary outcome.
Early dropouts are a major challenge to performing an
FITT analysis. Nearly half of the trials with repeated
follow-ups in this review reported early dropout after
randomization; nearly a quarter of them had more than
10%. In such cases, the most commonly favored approach
was to exclude those dropouts from the analysis; thus, 28 of
39 trials (72%) with early dropouts performed a PITT anal-
ysis and another seven (18%) performed a CC analysis.
Late dropouts are also a challenge to an FITT analysis.
Most trials with repeated follow-ups (75 of 80; 94%) re-
ported late dropouts; more than half had more than 10%
late dropouts, and a quarter had more than 20%. A quarter
of trials (18 of 75) with late dropouts excluded them from
the primary analysis. In a pragmatic trial, exclusion of par-
ticipants may limit interpretation of findings and an FITT
analysis is therefore recommended [1,3], but many trials
in this review chose instead to exclude participantswho had dropped out. Conceptually, if the analyzed-as-
randomized principle is disturbed in any way, and for
whatever reason, the chance of an imbalance in baseline
variables increases.
Trials in this review frequently reported the reasons for
the dropouts but failed to justify the assumptions made
regarding missingness. Definitive testing of the assump-
tions regarding missingness is not possibledcertainly in
regard to the assumption of the missing data mechanism
being nonignorable. However, some degree of testing is
achievable; for example, in a stratified (by treatment
group) comparison of observed data, differences between
responders and nonresponders may help to reject the pos-
sibility of an MCAR assumption [21]. However, the
assumption of ignorable missing data (as assumed by most
statistical approaches) is difficult to test formally, as it is
impossible to know with certainty whether the reason for
missingness is somehow related to the fact that the data
are missing or are related to any unobserved covariates.
Clearly, it is important to gather as much information as
possible on the reasons for missing data and on patient
characteristics that can predict missingness [23], as such
information can help justify (or not) an ignorable missing
data assumption. Trialists should consider the availability
of secondary sources (eg, general practice records) to
obtain outcome data when there are missing data from
the primary source. Furthermore, none of the trials consid-
ered the possibility of MNAR, and many failed to adopt
methods that are appropriate and valid under an MAR
assumption, which is a recommended neutral starting point
in many settings [14,22,23]. Importantly, the most
commonly applied method (LOCF) may not even be valid
under MCAR [17,23].4.1. Power calculation in anticipation of dropouts
In the review, 21% of trials (19 of 91) failed to report a
formal sample size calculation, contrary to CONSORT rec-
ommendations [41]. Sample size should relate to a prede-
termined primary outcome. Specification of a primary
outcome variable and primary end point guards against
changing the planned outcome and placing undue emphasis
on one that was not the original primary outcome. Of the 72
trials reporting a sample size calculation, 18 (25%) failed to
achieve adequate numbers at randomization and 62 (86%)
did not meet the target set for the primary end point. Partic-
ularly important in relation to missing data is how to ac-
count for loss of power due to dropouts in hypothesis
tests or confidence intervals [42]. One approach is to inflate
the sample size to take account of missing values; 28 of 72
trials (39%) reporting a sample size calculation adjusted the
sample size in this way. Such inflation of sample size as-
sumes that the loss of nominal power is proportional to
the amount of missing data. However, this assumption
may not be warranted. Little et al. [42] point out that infla-
tion of the sample size does not necessarily reduce bias and
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tion is very rarely justified. Therefore, power analyses that
account for missing data should be based on more plausible
MAR or MNAR assumptions [42].4.2. Baseline comparison
Exclusion of randomized subjects can affect the baseline
balance achieved through randomization. However,
although most trials reported the dropout rate between arms
and provided reasons for dropouts, many failed to compare
key baseline variables between subjects with and without
missing outcome data. Moreover, most trials evaluated
the differences in baseline characteristics between arms
based on number of subjects randomized rather than on
number analyzed, despite discrepancies between these
numbers. This oversight fails to locate (and hence leads
to failure to adjust for) any imbalance in baseline character-
istics between arms in the analysis data set. Many reports
highlighted the equality in the dropout rate between arms,
suggesting a view that an equal dropout rate would not lead
to a biased estimate of treatment effect. However, bias is a
function of both the frequency of and the reasons for the
missing values in each arm [20].4.3. Handling missing data
Although most trials with dropouts included them in the
primary analysis, most of these trials used inappropriate
methods to account for missing outcome data in the anal-
ysis, and inferences from these analyses may therefore be
biased. A CC analysis only includes subjects with complete
data. In trials with repeated follow-ups, standard statistical
methods, such as analysis of covariance, exclude subjects
for whom some intermediate measurements are available.
A quarter (18 of 75) of trials with repeated follow-ups that
reported late dropouts excluded them from the primary
analysis.
Several single imputation strategies are common in
RCTs [19]. These methods are generally not recommended
because they inadequately account for uncertainty in the
data and may produce biased estimates [22]. Many trials
(44 of 75; 60%) with repeated follow-ups used some sort
of single imputation. The findings of these trials are doubt-
ful, as many of these methods are not valid even under an
MCAR assumption [17,23]. In particular, the LOCF
approach makes a very strong assumption, which is un-
likely to be true, that the value of an outcome remains con-
stant after dropout. This was the most frequently used
imputation method in the review (in more than a third of
the trials with late dropouts) despite recommendations
against its use [22,23,43]. LOCF has been shown to be
common elsewhere [44,45].
A substantial proportion of trials used imputations that
require extreme assumptions; for example, the assumption
that dropouts are ‘‘nonresponders’’ or have no change frombaseline. In 16% (12 of 75) of trials with late dropouts, the
dropouts were simply classified as ‘‘failure’’ where the pri-
mary outcome was analyzed on a dichotomous scale (‘‘suc-
cess’’ or ‘‘failure’’). Additionally, in another four trials with
late dropouts, the missing data were replaced by baseline
data (a BOCF approach) where the primary outcome was
analyzed on a continuous scale. These imputations some-
times provide informative bounds on the effect of the
missing data but rarely produce unbiased estimates of treat-
ment effect.
Recently, MI has received substantial attention in the
literature as it helps to overcome the limitations of single
imputations [46]. The MI technique uses several stochastic
imputations to incorporate the uncertainty surrounding the
missing value and gives valid standard errors under
MAR. Despite evidence of increasing use of MI in the anal-
ysis of RCTs [36], only two trials in this review [47,48] per-
formed MI-based analyses and reported the results. Another
three trials claimed to have performed MI as a sensitivity
analysis but failed to report the results. Importantly, trials
that performed MI failed to report the procedure
adequately. Sterne et al. [46] suggested guidelines for re-
porting analyses based on MI to avoid pitfalls with its
application and aid interpretation of its results.
Similarly, analysis methods that make use of all avail-
able data in the presence of dropouts were infrequently
used. Likelihood-based mixed-effects models such as
MMRM can use all available longitudinal data without a
need to impute values and are valid when the dropout
mechanism is ignorable [33]. Only 8% (6 of 75) of trials
with late dropouts used MMRM to analyze longitudinal
outcome data. Additionally, MMRM was performed after
imputation of missing values using LOCF in two trials
[49,50], BOCF in one trial [51], and MI in another one
[48]. The use of imputations such as LOCF and BOCF un-
dermines the benefits of MMRM, and the results may not
be valid under MAR. Also, the use of MI before performing
the MMRM is unnecessary, as there is no obvious gain
from doing so [52].
Semiparametric regression-based methods such as
GEE can also use all available data in the presence of
dropouts and were used by two trials. However, standard
GEE methods are valid only under MCAR [53]. Weighted
GEE (where weight is assigned at the subject level and is
calculated as the inverse of the probability for dropping
out at the observed time of dropout) or MI-based GEE
(where MI is used before performing GEE) are preferred
over standard GEE because these methods can provide a
valid estimate of treatment effect under MAR [54]. No
trials in this study presented results based on these
methods.4.4. Sensitivity analysis
Many researchers agree that analysis based on an MAR
assumption is often a reasonable starting point [14,22,23].
23R. Joseph et al. / Journal of Clinical Epidemiology 68 (2015) 15e24However, one should always be open to the possibility that
the data are MNAR. One should, therefore, evaluate the
sensitivity of results to possible departures from the MAR
assumption by assuming a range of plausible MNAR mech-
anisms. Our study found sensitivity analyses to be infre-
quently and inappropriately used and insufficiently
reported. Moreover, trials that performed a sensitivity anal-
ysis used CC or single imputation methods, which may not
be justified given that MCAR is an unlikely scenario. Sensi-
tivity analyses that test the robustness of the primary and
other key outcome estimate(s) to plausible deviations from
underlying assumptions are strongly recommended. Along
with judicious sensitivity analyses, discussion around inter-
pretation and validity of the primary analysis findings is
highly recommended and should be an integral part of
any statistical report, unless perhaps the amount of missing
data is minimal [23].5. Conclusion
This review focuses specifically on recent trial publica-
tions for musculoskeletal conditions, although similar
dropout figures have been reported for RCTs covering a
broad spectrum of clinical areas [15]. Conceptually,
extrapolation of the findings to other areas using more
explanatory designs is questionable, given the different
methodological issues raised in connection with pragmatic
trials [7].
The findings of this study are comparable with those of
previous reviews [24e27] of trials published in general
medical journals. It appears that progress has not been
made in reducing the large proportion of trials that are inap-
propriately analyzed and that may therefore be prone to
erroneous estimates and conclusions. Given that missing
outcome data are not avoidable in most musculoskeletal tri-
als, researchers should ensure that missing values are
handled judiciously, in line with current best practice, and
should use methods of analysis that make appropriate as-
sumptions about missingness. Equally, such trials should
be reported in line with current guidelines. Because trials
with a large proportion of missing data are highly sensitive
to deviation from simple assumptions like MCAR and the
assumptions cannot be fully justified from the data, report-
ing of sensitivity analyses is advised.Author contributions
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